New Products: LifeCodexx's PraenaTest | GenomeWeb

LifeCodexx is now offering three options for its next-gen sequencing-based noninvasive fetal aneuploidy test, PraenaTest. The standard option includes testing for trisomies 21, 18, and 13. One option includes testing for only trisomy 21. An expanded option includes testing for trisomies 21, 18, and 13, as well as the determination of fetal gonosomal aneuploidy for singleton pregnancies, such as Turner, Triple X, Klinefelter, and XYY syndromes. In addition, starting in 2015, patients will be able to be refunded by their statutory health insurances for a trial period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.